Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
Under industry pressure, the Centers for Medicare & Medicaid Services (CMS) reversed a prior decision and will authorize an additional payment to hospitals under Medicare’s new technology add-on payment (NTAP) program for the cancer drug blinatumomab (Blincyto; Amgen) for use in patients with relapsed or refractory acute lymphoblastic leukemia (ALL).1,2 Blinatumomab is a bispecific T cell–engaging monoclonal antibody whose putative mechanism of action is targeting CD19+ cells for death by activating cytotoxic, CD3+ T cells.
Dhruva SS, Prasad V. Application of Medicare’s New Technology Add-on Payment Program for Blinatumomab. JAMA Oncol. 2016;2(2):165–166. doi:10.1001/jamaoncol.2015.5359
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: